New unemployment filings in Wisconsin edged higher last week, contrasting with a slight national decline and highlighting regional economic disparities as labor market signals remain mixed.
Missouri's inaugural month of legal sports betting attracted over $540 million in wagers, but aggressive promotions led to a net revenue loss for operators, even as the state collected millions in fees and taxes.
Axon Enterprise stock fell sharply this week, caught in a sector-wide downturn for software stocks driven by AI disruption fears and valuation concerns, despite a lack of company-specific negative news.
Amidst economic crosscurrents, a closer look at Ideal Power, NetSol Technologies, and Sono-Tek reveals companies executing distinct strategies to navigate growth and profitability challenges in the high-risk, high-reward penny stock arena.
American Express reported fourth-quarter earnings that slightly trailed analyst forecasts, prompting a share price decline. Despite the near-term miss, the company issued strong forward guidance for 2026 and announced a significant dividend hike, underscoring confidence in its long-term growth trajectory driven by card member spending and fee growth.
After soaring to unprecedented highs, copper prices have begun to retreat. Goldman Sachs forecasts a more significant market adjustment by mid-2026, driven by potential U.S. tariff policies and a disconnect from fundamental demand.
Financial planners are urging a shift in mindset: the date on your retirement party invitation matters less than the balance in your investment portfolio. We break down the calculations that show whether you're truly ready to leave the workforce.
A stunning reversal wiped out months of gains for precious metals on Friday, with gold futures tumbling to $4,800 and silver recording a historic single-day drop, sparking fears of a volatile new phase for commodity markets.
New unemployment filings in Wisconsin edged higher last week, diverging from a slight national decline and highlighting ongoing labor market fluctuations across states.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
Despite posting a Q4 net loss, Covenant Logistics signals a shift in market dynamics, with executives pointing to rising spot rates, secured contract increases, and a disciplined fleet strategy as precursors to a stronger performance by late 2026.
While major indices hold steady, a search for growth is turning the spotlight onto smaller companies. We examine three small-cap stocks—from insurance to banking to luxury watches—that are posting strong results and navigating unique challenges in the current market.
Shares of diabetes care innovator Insulet have tumbled nearly 10% year-to-date, sparking a fierce debate among investors. While a key valuation model suggests the stock is deeply undervalued, its sky-high P/E ratio tells a conflicting story. We examine the numbers and what they mean for the future of the Omnipod maker.
DoubleVerify's nomination for a Digiday award spotlights its News Accelerator initiative, a strategic push to bolster quality journalism and advertiser confidence in digital news environments. The move comes as the industry grapples with brand safety and seeks more transparent ad placements.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Despite a sharp pullback following gold's price dip, analysts remain bullish on SSR Mining, citing strong earnings potential and attractive valuation metrics even after its stellar run.
The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
Initial unemployment filings in Illinois fell last week, reflecting a modest improvement in local labor market conditions even as national numbers held steady.
RLI Corp's latest earnings report showcases robust underwriting performance and capital returns. However, a mixed share price trajectory and premium valuation metrics are prompting investors to question whether the stock's future growth is already priced in.
